학술논문
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
Document Type
article
Author
Farhad Ravandi; Gail J. Roboz; Andrew H. Wei; Hartmut Döhner; Christopher Pocock; Dominik Selleslag; Pau Montesinos; Hamid Sayar; Maurizio Musso; Angela Figuera-Alvarez; Hana Safah; William Tse; Sang Kyun Sohn; Devendra Hiwase; Timothy Chevassut; Francesca Pierdomenico; Ignazia La Torre; Barry Skikne; Rochelle Bailey; Jianhua Zhong; C. L. Beach; Herve Dombret
Source
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P